Trials / Completed
CompletedNCT02516085
Improved Muscle Function in Duchenne Muscular Dystrophy Through L-Arginine and Metformin
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- University Hospital, Basel, Switzerland · Academic / Other
- Sex
- All
- Age
- 7 Years – 10 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to show that the intake of L-arginine and metformin improves muscle function and delays disease progression in patients with Duchenne's muscular dystrophy.
Detailed description
This is an investigator-initiated, open-label, single-center, proof-of-concept-study. The study medication consists of L-arginine and metformin. The duration of the study is 16 weeks and comprehends one screening and four study visits.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Metformin | |
| DRUG | L-Arginine |
Timeline
- Start date
- 2012-01-01
- Primary completion
- 2012-10-01
- Completion
- 2012-10-01
- First posted
- 2015-08-05
- Last updated
- 2015-08-07
Source: ClinicalTrials.gov record NCT02516085. Inclusion in this directory is not an endorsement.